- PackSize
- 50ug/100ug
- Target
- CTLA-8
- Reactivity
- Human
- Applications
- ELISA, Bioactivity: FACS, Functional assay, Research in vivo
- Host Species
- Human
- Isotype
- [VH-VH'-H-Gamma1-VL-VL'-C-kappa]-dimer
- Conjugate/Modification
- --
- Recommended Dilution Ratio
- --
- Composition
- 0.01M PBS, pH 7.4.
- Purification Process
- Protein A/G purified from cell culture supernatant.
- Purity
- >95% as determined by SDS-PAGE.
- storageCondition
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
- Clonality
- Monoclonal
- Clone Number
- --
- Immunogen
- Mammalian Cells
- Alias
- CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A, TNF, Tumor necrosis factor ligand superfamily member 2, N-terminal fragment, ICD2, NTF, TNF-a, TNF-alpha, Tumor necrosis factor, TNFSF2, TNFA, Cachectin, ICD1
- Species
- --
- Gene ID-1
- Q16552 & P01375
- Uniprot
- --
- Background
- Remtolumab (ABT-122) is a dual-variable domain immunoglobulin that neutralises both tumor necrosis factor α (TNFα) and IL-17A. Remtolumab shows dual inhibition of TNFα and IL-17A. Remtolumab can be used for rheumatoid arthritis (RA) research.<br>
- Tissue Expression
- --
- Signaling_pathway
- --
- Research Areas
- --